Digoxin use in heart failure with reduced ejection fraction is addressed through a proposed practical precision medicine-based guide, despite its recent decline in prescriptions.
How can digoxin be utilized in a precision medicine-based approach for heart failure with reduced ejection fraction?
This paper proposes a practical precision medicine-based guide for the use of digoxin in heart failure with reduced ejection fraction, addressing its declining use and toxicity concerns.
Introduction: the paradox of digitalis therapy Digoxin holds a unique position in the history of cardiovascular medicine. Although it is the oldest drug in continuous use for heart failure (HF) treatment, there has been a sharp decline in prescriptions over the past two decades. Overshadowed by the advent of disease-modifying therapies and stigmatized due to concerns regarding toxicity, digoxin was relegated to a Class IIa recommendation in the Brazilian guideline and a third-line recommendation (Class IIb) in the major international ...
Germano Emílio Conceição‐Souza (Wed,) conducted a review in Heart Failure with Reduced Ejection Fraction. Digoxin was evaluated. Digoxin use in heart failure with reduced ejection fraction is addressed through a proposed practical precision medicine-based guide, despite its recent decline in prescriptions.